Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive disease characterized by myocardial accumulation of transthyretin amyloid fibrils [1]. The propensity to develop transthyretin aggregates may be genetically determined or related to senescence. Up to 20 years before the cardiomyopathy diagnosis, amyloid fibrils may deposit in tendons, leading to the development of carpal tunnel syndrome, biceps tendon rupture, trigger finger and lumbar spinal stenosis (LSS) [2]. Therefore, the presence of tenosynovial manifestations could potentially identify early cases of ATTR-CA, which might benefit the most from disease-modifying therapies [3].

In this study, we developed a screening protocol including the identification of potential patients with ATTR-CA from General practitioners based on tenosynovial manifestations, followed by a cardiological evaluation in an Amyloidosis Referral Center.